TY - JOUR
T1 - Adult chronic rhinosinusitis
AU - Bachert, Claus
AU - Marple, Bradley
AU - Schlosser, Rodney J.
AU - Hopkins, Claire
AU - Schleimer, Robert P.
AU - Lambrecht, Bart N.
AU - Bröker, Barbara M.
AU - Laidlaw, Tanya
AU - Song, Woo Jung
N1 - Funding Information:
C.B. serves in advisory boards for AstraZeneca, GlaxoSmithKline, Mylan, Novartis and Sanofi-Aventis. R.J.S. has served as a consultant for GlaxoSmithKline, Healthy Humming, Optinose, Sanofi, and Stryker and has received grant support from AstraZeneca, Optinose and Stryker. C.H. has served on advisory boards for AstraZeneca, Olympus, Sanofi and Smith & Nephew. R.P.S. is a consultant for Actobio Therapeutics, Allakos, Aqualung Therapeutics Corp., Astellas Pharm. Inc., AstraZeneca/Medimmune, Aurasense, BioMarck, Celgene Corp., Exicure, Genentech, Genzyme/Sanofi Corp., GlaxoSmithKline, Intersect ENT, Lyra Therapeutics, Merck, Otsuka, and Sanofi and he owns stocks or stock options for Allakos, Aqualung Therapeutics Corp., Aurasense, BioMarck, and Exicure. Furthermore, he owns Allakos Siglec-8 and Siglec-8 ligand related patents; as a result of the Allakos licensing agreement, per Johns Hopkins University policy, he may be entitled to a share of future royalties regarding the sale of Siglec-8 related products, although no such royalties exist at the time of writing. T.L. has served on scientific advisory boards for GlaxoSmithKline, Optinose, Regeneron and Sanofi-Genzyme. B.N.L. serves in advisory boards for GlaxoSmithKline, Novartis, OncoArendi and Argenx. All other authors declare no competing interests.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Chronic rhinosinusitis (CRS) occurs in >10% of the adult population in Europe and the USA and can be differentiated into CRS without nasal polyps and CRS with nasal polyps (CRSwNP). Both phenotypes are characterized by a high disease burden and an overlapping spectrum of symptoms, with facial pain and loss of smell being the most differentiating. Great progress has been made in the understanding of CRS pathophysiology: from the epithelium and epithelial–mesenchymal transition to innate and adaptive immunity pathways and, finally, on the role of eosinophils and Staphylococcus aureus in the persistence of disease. Although clinical manifestations and diagnostic tools (including nasal endoscopy and imaging) have undergone major changes over the past few years, management (including pharmacotherapy, surgery and biologics) has experienced enormous progress based on the growing knowledge of key mediators in severe CRSwNP. The introduction of endotyping has led to a differentiation of ‘tailored’ surgical approaches, focusing on the mucosal concept in those with severe CRSwNP and on the identification of patients eligible for extended surgery and possibly biologics in the future.
AB - Chronic rhinosinusitis (CRS) occurs in >10% of the adult population in Europe and the USA and can be differentiated into CRS without nasal polyps and CRS with nasal polyps (CRSwNP). Both phenotypes are characterized by a high disease burden and an overlapping spectrum of symptoms, with facial pain and loss of smell being the most differentiating. Great progress has been made in the understanding of CRS pathophysiology: from the epithelium and epithelial–mesenchymal transition to innate and adaptive immunity pathways and, finally, on the role of eosinophils and Staphylococcus aureus in the persistence of disease. Although clinical manifestations and diagnostic tools (including nasal endoscopy and imaging) have undergone major changes over the past few years, management (including pharmacotherapy, surgery and biologics) has experienced enormous progress based on the growing knowledge of key mediators in severe CRSwNP. The introduction of endotyping has led to a differentiation of ‘tailored’ surgical approaches, focusing on the mucosal concept in those with severe CRSwNP and on the identification of patients eligible for extended surgery and possibly biologics in the future.
UR - http://www.scopus.com/inward/record.url?scp=85094851778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094851778&partnerID=8YFLogxK
U2 - 10.1038/s41572-020-00218-1
DO - 10.1038/s41572-020-00218-1
M3 - Article
C2 - 33122665
AN - SCOPUS:85094851778
VL - 6
JO - Nature Reviews Disease Primers
JF - Nature Reviews Disease Primers
SN - 2056-676X
IS - 1
M1 - 86
ER -